Application of a propensity score to adjust for channelling bias with NSAIDs

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 6, 2004, Pages 345-353

  Morant, Steve V ^a,b   Pettitt, D ^c   MacDonald, T M ^a   Burke, T A ^d   Goldstein, J L ^e  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Cygnus Biostatistics Ltd   (United Kingdom)

^c PFIZER INC   (United States)

^d Pharmacia   (United States)

^e UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Coxibs; Gastrointestinal haemorrhage; General practice research database; Nonsteroidal anti inflammatory drugs; Propensity score

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT;

AGE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEMATEMESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MELENA; PRESCRIPTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; UPPER GASTROINTESTINAL BLEEDING;

EID: 2942706004     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.946     Document Type: Article

References (17)

1. Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D, Roszko P, Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med 2000; 160: 2947-2954.
2. Martin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19 087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000; 50: 35-42.
3. Lanes SF, Garcia Rodriguez LA, Hwang GE. Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin. Pharmacoepidemiol Drug Safe 2000; 9: 113-117.
4. Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27: 1876-1883.
5. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
6. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681-1690.
7. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-1933.
8. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160: 2998-3003.
9. McKenna F, Arguelles L, Burke T, Lefkowith J, Geis GS. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. Clin Exp Rheumatol 2002; 20: 35-43.
10. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis The CLASS study: a randomised controlled trial. JAMA 2000; 284: 1247-1255.
11. McDonald TM, Morant SV, Goldstein JL, Burke TA, Pettit D. The incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs and older non-specific nonsteroidal anti-inflammatory drugs. Gut 2003; 52: 1-6
12. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-425.
13. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302: 766-768.
14. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
15. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10: 1665-1677.
16. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. Br Med J 1997; 315: 1333-1337.
17. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003; 158: 280-287.